Jazz Pharmaceuticals plc
JAZZ · XNASCIK 1232524fmd_1QE80HTQ87APFWNDPVMZ3DJYHCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,488 | 1,619 | 1,891 | 2,162 | 2,364 | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 |
| Research and development | 162 | 198 | 227 | 300 | 335 | 506 | 590 | 850 | 884 | 783 |
| Selling, general and administrative | 503 | 544 | 684 | 737 | 854 | 1,452 | 1,417 | 1,343 | 1,385 | 1,809 |
| Total operating expenses | 896 | 1,090 | 1,276 | – | – | – | – | – | – | – |
| Operating income | 592 | 529 | 615 | 532 | 378 | 170 | (66) | 579 | 717 | (430) |
| Interest expense | 28 | 38 | 57 | 63 | 88 | 90 | 33 | 33 | – | – |
| Interest and investment income | – | 4 | 17 | 21 | 11 | 2 | 12 | 65 | 106 | 86 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | 532 | 441 | 529 | 454 | 275 | (113) | (373) | 298 | 470 | (628) |
| Income tax expense | 135 | (48) | 80 | (73) | 34 | 216 | (159) | (120) | (91) | (272) |
| Net income from continuing operations | 397 | 489 | 449 | 527 | 242 | (329) | (214) | 418 | 562 | (355) |
| Net income | 397 | 488 | 447 | 523 | 239 | (330) | (224) | 415 | 560 | (356) |
| Net income to common shareholders | – | – | – | – | – | (330) | (224) | 440 | 571 | (356) |